Heptamethine cyanine based 64Cu-PET probe PC-1001 for cancer imaging: Synthesis and in vivo evaluation

Nuclear Medicine and Biology

Volumn 40, Issue 3, 2013, Pages 351-360

  Xiao, Li ^a   Zhang, Yi ^a   Yue, Wei ^a   Xie, Xiuzhen ^a   Wang, Ji ping ^a   Chordia, Mahendra D ^a   Chung, Leland W K ^b   Pan, Dongfeng ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Cu 64; PET imaging probe; Tumor targeting; Xenograft

Indexed keywords

COPPER 64; COPPER PC 1001 CU 64; CYANINE DYE; ORGANIC ANION TRANSPORTER; PC 1001; RADIOISOTOPE; TETRAXETAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CELL STRAIN MCF 7; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; FLUORESCENCE IMAGING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; TUMOR VOLUME; TUMOR XENOGRAFT; VALIDATION PROCESS;

ANIMALS; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CARBOCYANINES; CELL TRANSFORMATION, NEOPLASTIC; CHEMISTRY TECHNIQUES, SYNTHETIC; COPPER RADIOISOTOPES; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MCF-7 CELLS; MICE; POSITRON-EMISSION TOMOGRAPHY; SPECTROMETRY, FLUORESCENCE; TUMOR BURDEN;

EID: 84875255927     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.01.001     Document Type: Article

References (38)

1. van der Meel R., Gallagher W.M., Oliveira S., O'Connor A.E., Schiffelers R.M., Byrne A.T. Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. Drug Discov Today. 2010, 15:102-114. 10.1016/j.drudis.2009.12.003.
2. Kaur S., Venktaraman G., Jain M., Senapati S., Garg P.K., Batra S.K. Recent trends in antibody-based oncologic imaging. Cancer Lett. 2012, 315:97-111. 10.1016/j.canlet.2011.10.017.
3. Leonard F. Imaging and cancer: a review. Mol Oncol 2008, 2:115-152. 10.1016/j.molonc.2008.04.001.
4. Etzioni R., Urban N., Ramsey S., McIntosh M., Schwartz S., Reid B., et al. The case for early detection. Nature Reviews Cancer. 2003, 3:243-252. 10.1038/Nrc1041.
5. Glunde K., Pathak A.P., Bhujwalla Z.M. Molecular-functional imaging of cancer: to image and imagine. Trends Mol Med. 2007, 13:287-297. 10.1016/j.molmed.2007.05.002.
6. Blasberg R.G. Imaging update: new windows. New views. Clin Cancer Res. 2007, 13:3444-3448. 10.1158/1078-0432.ccr-07-0936.
7. Ozkan E., Soydal C., Araz M., Kir K.M., Ibis E. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels. Nucl Med Commun. 2012, 33:395-402. 10.1097/MNM.0b013e32834f7dbe.
8. Phelps M.E. Positron emission tomography provides molecular imaging of biological processes. Proc Nat Acad Sci. 2000, 97:9226-9233. 10.1073/pnas.97.16.9226.
9. Xiao L., Zhang Y., Liu Z.Q., Yang M., Pu L., Pan D.F. Synthesis of the cyanine 7 labeled neutrophil-specific agents for noninvasive near infrared fluorescence imaging. Bioorg Med Chem Lett. 2010, 20:3515-3517. 10.1016/j.bmcl.2010.04.136.
10. Chen X., Conti P.S., Moats R.A. In vivo near-infrared fluorescence imaging of integrin αvβ3 in brain tumor xenografts. Cancer Res. 2004, 64:8009-8014. 10.1158/0008-5472.can-04-1956.
11. Luo S., Zhang E., Su Y., Cheng T., Shi C. A review of NIR dyes in cancer targeting and imaging. Biomaterials. 2011, 32:7127-7138. 10.1016/j.biomaterials.2011.06.024.
12. Wang W., Ke S., Kwon S., Yallampalli S., Cameron A.G., Adams K.E., et al. A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Bioconjugate Chem. 2007, 18:397-402. 10.1021/bc0602679.
13. Cai W., Chen K., Li Z.B., Gambhir S.S., Chen X. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med. 2007, 48:1862-1870. 10.2967/jnumed.107.043216.
14. Chen K., Li Z.-B., Wang H., Cai W., Chen X. Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging 2008, 35:2235-2244. 10.1007/s00259-008-0860-8.
15. Olson E.S., Jiang T., Aguilera T.A., Nguyen Q.T., Ellies L.G., Scadeng M., et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci. 2010, 107:4311-4316. 10.1073/pnas.0910283107.
16. Weissleder R. Molecular imaging in cancer. Science 2006, 312:1168-1171. 10.1126/science.1125949.
17. Yang X., Shi C., Tong R., Qian W., Zhau H.E., Wang R., et al. Near IR heptamethine cyanine dye-mediated cancer imaging. Clin Cancer Res. 2010, 16:2833-2844. 10.1158/1078-0432.ccr-10-0059.
18. Yue W., Wang J.-P., Hamilton C.J., Demers L.M., Santen R.J. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res. 1998, 58:927-932.
19. Cui Y., Konig J., Leier I., Buchholz U., Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001, 276:9626-9630. 10.1074/jbc.M004968200.
20. Yamaguchi H., Okada M., Akitaya S., Ohara H., Mikkaichi T., Ishikawa H., et al. Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006, 47:1196-1202. 10.1194/jlr.M500532-JLR200.
21. Yue W., Zhou D., Chen S., Brodie A. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res. 1994, 54:5092-5095.
22. Henary M., Pannu V., Owens E.A., Aneja R. Near infrared active heptacyanine dyes with unique cancer-imaging and cytotoxic properties. Bioorg Med Chem Lett. 2012, 22:1242-1246. 10.1016/j.bmcl.2011.11.070.
23. Chen X., Peng X., Cui A., Wang B., Wang L., Zhang R. Photostabilities of novel heptamethine 3H-indolenine cyanine dyes with different N-substituents. J Photochem Photobiol A-Chem. 2006, 181:79-85. 10.1016/j.jphotochem.2005.11.004.
24. Blagosklonny M.V., Pressler H., Sissung T.M., Venzon D., Price D.K., Figg W.D. Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS ONE. 2011, 6:e20372. 10.1371/journal.pone.0020372.
25. Wlcek K. Expression of organic anion transporter polypeptides (OATPs) in human breast carcinoma. Sci Pharm 2009, 77:196. 10.3797/scipharm.oephg.21.SL-29.
26. Briasoulis E., Valentinos K., Loakim E., Martin S., Andreas T., Ioannis S., et al. Expression of organic anion-transporting polypeptides 1B3, 1B1, and 1A2 in human pancreatic cancer reveals a new class of potential therapeutic targets. Oncol Targets Ther 2011, 4:27-32. 10.2147/ott.s16706.
27. Locke L.W., Chordia M.D., Zhang Y., Kundu B., Kennedy D., Landseadel J., et al. A novel neutrophil-specific PET imaging agent: cFLFLFK-PEG-(64)Cu. J Nucl Med. 2009, 50:790-797. 10.2967/jnumed.108.056127.
28. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin αvβ3 targeted radiotracers for tumor imaging. Molecular Pharmacolgy 2006, 3:472-487.
29. Vvere A.L.L.J. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Transactions. 2007, 21:4893-4902.
30. Höglund J.S.A., Antoni G., Gustavsson S.Å., Långström B., Ringheim A., Sörensen J., et al. 18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med 2011, 55:720-725.
31. Kenny L.M., Vigushin D.M., Al-Nahhas A., Osman S., Luthra S.K., Shousha S., et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Research. 2005, 65:10104-10112.
32. Fukuda H., Paredes S., Batlle A.M. Tumor-localizing properties of porphyrins. In vitro studies using the porphyrin precursor, aminolevulinic acid, in free and liposome encapsulated forms. Drug Des Deliv. 1989, 5:133-139.
33. Ben-Dror S., Bronshtein I., Wiehe A., Roder B., Senge M.O., Ehrenberg B. On the correlation between hydrophobicity, liposome binding and cellular uptake of porphyrin sensitizers. Photochem Photobiol. 2006, 82:695-701. 2005-09-01-RA-669 [pii]. 10.1562/2005-09-01-RA-669.
34. Smith K., Malatesti N., Cauchon N., Hunting D., Lecomte R., van Lier J.E., et al. Mono- and tri-cationic porphyrin-monoclonal antibody conjugates: photodynamic activity and mechanism of action. Immunology. 2011, 132:256-265. 10.1111/j.1365-2567.2010.03359.x.
35. Donald P.J., Cardiff R.D., He D.E., Kendall K. Monoclonal antibody-porphyrin conjugate for head and neck cancer: the possible magic bullet. Otolaryngol Head Neck Surg. 1991, 105:781-787.
36. Lucienne J.-J. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?. Drug Discov Today. 2008, 13:1099-1106. 10.1016/j.drudis.2008.09.005.
37. Kratochwil N.A., Huber W., Müller F., Kansy M., Gerber P.R. Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol. 2002, 64:1355-1374. 10.1016/s0006-2952(02)01074-2.
38. Xiao L., Zhang Y., Berr S.B., Chordia M., Pramoonjago P., Pu L., et al. A novel near-infrared fluorescence imaging probe for in vivo neutrophil tracking. Mol Imaging. 2011, 11:1-11.